Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 130,101	$ 122,162
Marketable securities, short-term	47,504	72,075
Prepaid expenses and other current assets	2,724	4,424
Total current assets	180,329	198,661
Marketable securities, long-term	15,837	31,619
Property and equipment, net	165	36
Right-of-use asset	105	0
Other assets	151	14
Total assets	196,587	230,330
Current liabilities
Accounts payable	1,640	1,088
Accrued clinical trial expenses	2,717	147
Accrued expenses and other current liabilities	3,350	3,912
Operating lease liability, current portion	105	0
Total current liabilities	7,812	5,147
Total liabilities	7,812	5,147
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2022 and 2021	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized and 41,025,062 and 40,473,270 shares issued and outstanding as of December 31, 2022 and 2021, respectively	4	4
Additional paid-in capital	359,949	352,981
Accumulated deficit	(170,427)	(127,571)
Accumulated other comprehensive loss	(751)	(231)
Total stockholders’ equity	188,775	225,183
Total liabilities and stockholders’ equity	$ 196,587	$ 230,330